Modern approaches to treating chronic myelogenous leukemia
- PMID: 18706263
- DOI: 10.1007/s11912-008-0057-0
Modern approaches to treating chronic myelogenous leukemia
Abstract
Over the past decade, the treatment of chronic myelogenous leukemia (CML) has gone through significant advances. Once an invariably fatal disease without stem cell transplant, it has since become one of the most manageable hematologic malignancies with good long-term outcomes. However, patients are not cured and require life-long treatment, and unfortunately, some of these patients develop resistant disease that progresses despite our best treatments. As our understanding of CML continues to grow, the repertoire of drugs available for successful treatment also increases. The following review discusses the current and future therapies for CML.
Similar articles
-
Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.Clin Ther. 2007 Nov;29(11):2289-308. doi: 10.1016/j.clinthera.2007.11.005. Clin Ther. 2007. PMID: 18158072 Review.
-
Targeted chronic myeloid leukemia therapy: Seeking a cure.Am J Health Syst Pharm. 2007 Dec 15;64(24 Suppl 15):S9-15. doi: 10.2146/ajhp070482. Am J Health Syst Pharm. 2007. PMID: 18056932 Review.
-
Chronic myelogenous leukemia in chronic phase.Curr Treat Options Oncol. 2001 Jun;2(3):245-52. doi: 10.1007/s11864-001-0038-0. Curr Treat Options Oncol. 2001. PMID: 12057124 Review.
-
Chronic myelogenous leukaemia--new therapeutic principles.J Intern Med. 2001 Jul;250(1):3-9. doi: 10.1046/j.1365-2796.2001.00823.x. J Intern Med. 2001. PMID: 11454136 Review.
-
Bcr-Abl inhibition as a modality of CML therapeutics.Biochim Biophys Acta. 2001 Aug 31;1551(1):M11-8. doi: 10.1016/s0304-419x(01)00022-1. Biochim Biophys Acta. 2001. PMID: 11553417 Review. No abstract available.
Cited by
-
Novel Mechanism by a Bis-Pyridinium Fullerene Derivative to Induce Apoptosis by Enhancing the MEK-ERK Pathway in a Reactive Oxygen Species-Independent Manner in BCR-ABL-Positive Chronic Myeloid Leukemia-Derived K562 Cells.Int J Mol Sci. 2022 Jan 11;23(2):749. doi: 10.3390/ijms23020749. Int J Mol Sci. 2022. PMID: 35054935 Free PMC article.
-
Report of chronic myelogenous leukemia in chronic phase from, Asian Institute of Oncology, Mumbai, 2002-2010.Indian J Med Paediatr Oncol. 2013 Jul;34(3):168-71. doi: 10.4103/0971-5851.123717. Indian J Med Paediatr Oncol. 2013. PMID: 24516300 Free PMC article.
-
Changing trends of chronic myeloid leukemia in greater Mumbai, India over a period of 30 years.Indian J Med Paediatr Oncol. 2011 Apr;32(2):96-100. doi: 10.4103/0971-5851.89792. Indian J Med Paediatr Oncol. 2011. PMID: 22174498 Free PMC article.
-
Direct and indirect effects of IFN-α2b in malignancy treatment: not only an archer but also an arrow.Biomark Res. 2022 Sep 14;10(1):69. doi: 10.1186/s40364-022-00415-y. Biomark Res. 2022. PMID: 36104718 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials
Miscellaneous